PRRT Indications Guidelines: Who to Treat
The webinar recording is now available. Members, please login here and select "Webinars" from the "Member Only Links"
Speakers: Thomas Hope, MD, University of California, San Francisco; and Jonathan Strosberg, MD, Moffitt Cancer Center
Credit Type/Info: AMA, SAM, VOICE
PRRT Procedure Guidelines: How to Treat - Procedure Standard for Somatostatin Receptor Based PRRT with Lu-DOTATATE
The webinar recording is now available. Members, please login here and select "Webinars" from the "Member Only Links"
Speakers: Daniel Pryma, MD, University of Pennsylvania; and Amanda Abbott, MS, CNMT, RT(N)(CT), PET, Dana-Farber Cancer Institute
Credit Type/Info: AMA, SAM, VOICE
With access to PRRT on the rise, representatives from the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have collaborated to develop a practical consensus guideline for the administration of Lu-DOTATATE. As part of that collaboration NANETS and SNMMI are jointly presenting a three-part series of PRRT training webinars.
PRRT Indications Guidelines: Who to Treat
The second webinar in the series, Indications Guidelines: Who to Treat, will be presented September 5, 2019, at 2:00 pm ET. Presenters for this webinar are Thomas Hope, MD, University of California, San Francisco and Jonathan Strosberg, MD, Moffitt Cancer Center. Please watch for further details about this important educational training tool.
Learning Objectives:
- Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape
- Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life
- Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity
- Discuss relative and absolute contraindications to treatment
The first webinar, PRRT Procedure Guidelines: How to Treat - Procedure Standard for Somatostatin Receptor Based PRRT with Lu-DOTATATE, which was presented on July 16, defined the new peptide receptor radionuclide therapy (PRRT) procedure standards that will help improve the quality of service to patients. The webinar was very well-attended and we want to thank the presenters, Daniel Pryma, MD, University of Pennsylvania, Perelman School of Medicine, and Amanda Abbott, MS, CNMT, RT(N)(CT), PET, Dana Farber Cancer Institute, for their work on this presentation, which will be available online soon. Watch for details on social media and on the NANETS website.